MedTrace Logo

Avelumab and M1774 in ARID1A-mutated Endometrial Cancer

NCT06518564 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 25

Last updated 2026-01-07

No results posted yet for this study

Summary

The purpose of this research study is to see if the combination of study drugs avelumab and M1774 is effective and safe for participants with endometrial cancer.

The names of the study drugs involved in this study are:

* Avelumab (a type of human IgG1 antibody)
* M1774 (a type of ATR inhibitor)

Conditions

Interventions

DRUG

Avelumab

Human IgG1 antibody, 20mL single-use vials, via intravenous (into the vein) infusion per protocol.

DRUG

M1774

Ataxia Telangiectasia and Rad3-related protein (ATR) inhibitor, 30 and 50 mg capsules, taken orally per protocol.

Sponsors & Collaborators

  • EMD Serono

    collaborator INDUSTRY

  • The Applebaum Foundation

    collaborator UNKNOWN

  • Panagiotis Konstantinopoulos, MD, PhD

    lead OTHER

Principal Investigators

  • Panagiotis Konstantinopoulos, MD, PhD · Dana-Farber Cancer Institute

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-11-14
Primary Completion
2027-08-31
Completion
2029-08-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06518564 on ClinicalTrials.gov